Research & Development
Gencurix awarded FDA's EUA for GenePro SARS-CoV-2 Test, with screening of up to 384 samples simultaneously
25 June 2020 -

Korean molecular diagnostic company Gencurix Inc reported on Wednesday that the US Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its GenePro SARS-CoV-2 Test, a diagnostic kit for COVID-19.

This is the second RT-PCR test launched by Gencurix following its first test assay, GenePro COVID-19 Detection Test, which was released in March.

Advantages of the GenePro SARS-CoV-2 Test include simultaneous monitoring of up to 384 samples, allowing high throughput screening of the novel coronavirus.

With the FDA's EUA, Gencurix is now able to provide its COVID-19 detection tests across the United States.



Related Headlines